Lion Biotechnologies, Inc. (IOVA) Given Buy Rating at HC Wainwright
Lion Biotechnologies, Inc. (NASDAQ:IOVA)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Monday. They presently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 98.76% from the stock’s current price.
Several other research firms also recently issued reports on IOVA. Oppenheimer Holdings, Inc. set a $13.00 price target on shares of Lion Biotechnologies and gave the company a “buy” rating in a research note on Thursday, October 12th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Lion Biotechnologies in a research note on Sunday, October 29th. FBR & Co reaffirmed a “buy” rating and set a $17.50 price target on shares of Lion Biotechnologies in a research note on Wednesday, October 25th. Finally, Zacks Investment Research raised shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.53.
Lion Biotechnologies (IOVA) traded up $0.20 during mid-day trading on Monday, hitting $8.05. 517,300 shares of the stock traded hands, compared to its average volume of 363,658. Lion Biotechnologies has a 12-month low of $4.45 and a 12-month high of $8.60.
Lion Biotechnologies (NASDAQ:IOVA) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). sell-side analysts forecast that Lion Biotechnologies will post -1.37 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Lion Biotechnologies, Inc. (IOVA) Given Buy Rating at HC Wainwright” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/13/lion-biotechnologies-inc-iova-given-buy-rating-at-hc-wainwright.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. raised its stake in Lion Biotechnologies by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 222,015 shares of the biotechnology company’s stock worth $1,721,000 after buying an additional 12,883 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Lion Biotechnologies by 44.2% in the third quarter. Wells Fargo & Company MN now owns 103,528 shares of the biotechnology company’s stock worth $801,000 after purchasing an additional 31,724 shares during the period. Trexquant Investment LP acquired a new stake in Lion Biotechnologies in the third quarter worth $307,000. JPMorgan Chase & Co. grew its holdings in Lion Biotechnologies by 63.4% in the third quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock worth $14,059,000 after purchasing an additional 690,527 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Lion Biotechnologies in the third quarter worth $133,000. 65.76% of the stock is owned by institutional investors and hedge funds.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.